Literature DB >> 22179281

A new synthesis for antibody-mediated immunity.

Arturo Casadevall1, Liise-Anne Pirofski.   

Abstract

The view that immunoglobulins function largely by potentiating neutralization, cytotoxicity or phagocytosis is being replaced by a new synthesis whereby antibodies participate in all aspects of the immune response, from protecting the host at the earliest time of encounter with a microbe to later challenges. Perhaps the most transformative concept is that immunoglobulins manifest emergent properties, from their structure and function as individual molecules to their interactions with microbial targets and the host immune system. Given that emergent properties are neither reducible to first principles nor predictable, there is a need for new conceptual approaches for understanding antibody function and mechanisms of antibody immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22179281      PMCID: PMC3589717          DOI: 10.1038/ni.2184

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  80 in total

1.  Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.

Authors:  Jerome P Jayasekera; E Ashley Moseman; Michael C Carroll
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

2.  The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen.

Authors:  Marcela Torres; Narcis Fernández-Fuentes; András Fiser; Arturo Casadevall
Journal:  J Biol Chem       Date:  2007-03-12       Impact factor: 5.157

3.  Bactericidal action of a complement-independent antibody against relapsing fever Borrelia resides in its variable region.

Authors:  Timothy J LaRocca; Laura I Katona; David G Thanassi; Jorge L Benach
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

4.  Tyrosine phosphorylation and lipid raft association of pseudorabies virus glycoprotein E during antibody-mediated capping.

Authors:  Ann S Desplanques; Hans J Nauwynck; Kelly Tilleman; Dieter Deforce; Herman W Favoreel
Journal:  Virology       Date:  2007-01-22       Impact factor: 3.616

5.  A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

Authors:  Kevin Fabrizio; Abraham Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

6.  Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection.

Authors:  Paul J Maglione; Jiayong Xu; Arturo Casadevall; John Chan
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

7.  Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein.

Authors:  Peter T Beernink; Jo Anne Welsch; Michal Bar-Lev; Oliver Koeberling; Maurizio Comanducci; Dan M Granoff
Journal:  Infect Immun       Date:  2008-06-30       Impact factor: 3.441

8.  B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis.

Authors:  Paul J Maglione; Jiayong Xu; John Chan
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

9.  Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.

Authors:  Haijun Tian; Sarah Weber; Peter Thorkildson; Thomas R Kozel; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

10.  Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence.

Authors:  Antonella Torosantucci; Paola Chiani; Carla Bromuro; Flavia De Bernardis; Angelina S Palma; Yan Liu; Giuseppina Mignogna; Bruno Maras; Marisa Colone; Annarita Stringaro; Silvia Zamboni; Ten Feizi; Antonio Cassone
Journal:  PLoS One       Date:  2009-04-28       Impact factor: 3.240

View more
  54 in total

Review 1.  Immunoglobulin class-switch DNA recombination: induction, targeting and beyond.

Authors:  Zhenming Xu; Hong Zan; Egest J Pone; Thach Mai; Paolo Casali
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

2.  Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.

Authors:  Kening Wang; Georgia D Tomaras; Sinthujan Jegaskanda; M Anthony Moody; Hua-Xin Liao; Kyle N Goodman; Phillip W Berman; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayapan; Jaranit Kaewkungwal; Barton F Haynes; Jeffrey I Cohen
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 3.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  John Chan; Simren Mehta; Sushma Bharrhan; Yong Chen; Jacqueline M Achkar; Arturo Casadevall; JoAnne Flynn
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

4.  SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.

Authors:  Arturo Casadevall; Michael J Joyner; Liise-Anne Pirofski
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

5.  Antibody, but not B-cell-dependent antigen presentation, plays an essential role in preventing Chlamydia systemic dissemination in mice.

Authors:  Priyangi A Malaviarachchi; Miguel A B Mercado; Stephen J McSorley; Lin-Xi Li
Journal:  Eur J Immunol       Date:  2020-03-12       Impact factor: 5.532

6.  Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections.

Authors:  Laura Haynes; Frank M Szaba; Sheri M Eaton; Lawrence W Kummer; Paula A Lanthier; Ashlee H Petell; Debra K Duso; Deyan Luo; Jr-Shiuan Lin; Julie S Lefebvre; Troy D Randall; Lawrence L Johnson; Jacob E Kohlmeier; David L Woodland; Stephen T Smiley
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

Review 7.  Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.

Authors:  Min Yu; Zonghai Li
Journal:  Front Med       Date:  2017-08-05       Impact factor: 4.592

Review 8.  Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

Review 9.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

Review 10.  Cryptococcal therapies and drug targets: the old, the new and the promising.

Authors:  Carolina Coelho; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2016-04-08       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.